In brief
Lynn Dekleva's transition from lobbyist to head of a critical office at the Environmental Protection Agency has sparked concern regarding the agency's handling of chemical regulations, particularly regarding formaldehyde.
In a notable shift, Lynn Dekleva has stepped into a senior position at the Environmental Protection Agency (EPA), where she now oversees the approval of new chemicals. This transition comes amidst heightened scrutiny over formaldehyde—a chemical utilized widely in furniture, textiles, and embalming—that has been linked to cancer and serious respiratory issues. During her previous tenure as a lobbyist for the American Chemistry Council, Dekleva led efforts to block regulatory measures aimed at controlling formaldehyde, culminating in a significant campaign against the EPA’s initiatives to regulate the substance more tightly. Her lobbying was characterized by aggressive strategies that alarmed even the most experienced officials within the EPA, particularly when they initiated their 2021 push to impose stricter regulations on formaldehyde.Dr. Dekleva, who spent 32 years working with the chemical giant DuPont prior to her stint at the EPA under the Trump administration, has now been handed a pivotal role that allows her to influence policies surrounding chemical approvals. She is under pressure from her previous employer, the American Chemistry Council, to soften the agency's stance on formaldehyde and do away with certain risk assessment programs meant to protect human health.This push for regulatory revision is reflective of a broader agenda from the chemical industry to streamline the EPA's approval processes, advocating for faster safety reviews of new chemicals—an initiative that sits squarely within Dekleva's responsibilities at the agency. The council’s current president, Chris Jahn, has publicly stated an intention to mitigate what they consider “unnecessary regulation” of chemicals, linking the nation's health and economic security to the chemical industry’s prosperity.The reshuffle at the EPA, which has also seen former council lobbyist Nancy Beck return in a role focused on existing chemical oversight, raises eyebrows about the interplay between industry interests and public health safety. As the EPA continues to navigate these complex waters, the implications of their decisions could have lasting effects on environmental health standards and chemical safety regulations in the United States.
